Jefferies Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Jefferies Group’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,450	Closed	-$38K	–	2362
2018 Q4	$38K	Buy	+10,450	New	+$71.2K	﹤0.01%	2050

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group's CRVS Position: Q1 2019 in Review

Jefferies Group sold out of Corvus Pharmaceuticals (CRVS) in Q1 2019, closing a stake of 10,450 shares — an estimated $38K sold.

Jefferies Group first reported a position in CRVS in Q4 2018 and held it in 1 quarter. The position peaked at $38K in Q4 2018. 58 funds tracked by Wall St. Rank hold CRVS as of Q1 2019.

Jefferies Group reported no remaining Corvus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Jefferies Group sold 10,450 Corvus Pharmaceuticals shares in Q1 2019, an estimated $38K.
Jefferies Group first reported a position in Corvus Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Jefferies Group's Corvus Pharmaceuticals position peaked at $38K in Q4 2018.
58 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.